Skip to content
HCN Grants Est. 2026
No. RFA-FD-25-020 · Food and Drug Administration
Open

Reissue of RFA-FD-23-001- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)

Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated

At a glance

This program funds clinical trials of orphan products for rare diseases that address unmet needs. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, governments, tribal entities, foreign organizations, and certain community-based and faith-based organizations. The award budget may be up to $650,000 in total costs per year for years 1 through 4, with up to an additional $250,000 per year for innovative and efficient trial approaches, for a maximum of $900,000 per year. The project period can be up to 4 years, with continued support after year 1 depending on annual appropriations, funding availability, performance, and regulatory compliance.

AI-generated summary — verify against the announcement

What it funds

  • Agriculture
  • Consumer Protection
  • Food and Nutrition
  • Research & Discovery
  • Patients & People with Health Conditions
  • Biomedical & Disease Research
Official description from grants.gov

The purpose of this Notice of Funding Opportunity (NOFO) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development.

Who can apply

  • Others
Geographic restriction None found in the announcement — likely nationwide